Research use only. Not for human or veterinary use.
Lab reports
Analysis reportAll specifications met

Retatrutide 20mg

Peptide Stock ref. PSV-2610-RT20-02

Lot
CP01260924220X
Manufactured
24 September 2026
Tested by
Accumark Labs
Analysed
20 October 2026
Purity99.61%HPLC, 220 nm
Content per vial19.277 mg96.4% of 20 mg label claim
IdentityConfirmedHPLC

Test results

TestSpecificationResultOutcome
IdentityRetatrutideConformsPass
Quantity per vialAs measured19.277 mg (96.4% of claim)Reported
Purity (HPLC)≥ 98%99.607%Pass
Endotoxin (USP <85> LAL)< 350 EU/vialBelow LOQ (50 EU/vial)Pass

About this report

Analysis reportAll specifications met

Retatrutide 20mg

Peptide Stock ref. PSV-2610-RT20-01

Lot
CP01260924220X
Manufactured
24 September 2026
Tested by
Bioviridian
Analysed
20 October 2026
Purity99.84%RP-HPLC, 214 nm
Content per vial21.35 mg106.8% of 20 mg label claim
IdentityConfirmedLC-MS/MS

Test results

TestSpecificationResultOutcome
Identity (LC-MS/MS)RetatrutideRetatrutidePass
Content (HPLC quantitation)—21.35 mg (106.8% of claim)Pass
Overall purity (RP-HPLC 214 nm)—99.84%Pass

About this report

← All lab reports